Trial met its primary endpoint, with 64.3% of patients receiving etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR =.
Milestone Pharmaceuticals (MIST) Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The Scientific Advisory Board Will Develop the Company Clinical Trial Strategy, Ensure Alignment with Current Trends in Cardiac Pacing for Heart Failure Patients and Provide Input to the Pacertool
/PRNewswire/ Pacertool AS, a Norwegian emerging medical device company, today announced that the company has established a world-class Scientific Advisory.
The statement provides data showing the potential value of how sleep-disordered breathing treatment affects cardiac arrhythmias beneficially and thereby can improve patient outcomes.